Australia markets closed

Prescient Therapeutics Limited (PTX.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1750+0.0100 (+6.06%)
At close: 04:10PM AEST

Prescient Therapeutics Limited

100 Albert Road
Level 4
Melbourne, VIC 3205
Australia
61 3 9692 7222
https://ptxtherapeutics.com

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 

Key executives

NameTitlePayExercisedYear born
Mr. Steven Lee Yatomi-ClarkeMD, CEO & Director454.89kN/AN/A
Ms. Melanie Jaye Leydin B.Bus, C.A., CACFO & Company Sec.158.4kN/A1973
Ms. Leanne WestDirector of Clinical Affairs & OperationsN/AN/AN/A
Dr. Terrence G. ChewChief Medical OfficerN/AN/A1947
Dr. James D. Winkler Ph.D.Head of Bus. Devel.N/AN/A1955
Ms. Rebecca LimSr. VP of Scientific AffairsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Corporate governance

Prescient Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.